Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-275183 + Pemetrexed in Recurrent NSCLC
NCT00103831Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Primary completion
- May 2005
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 2 trial of bms-275183 in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Status: completed.
02
Drugs
bms-275183
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00103831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103831.